logo
Plus   Neg
Share
Email

CNH Board Announces Proposals To 2012 Annual General Meeting Of Shareholders

CNH Global N.V. (CNH) said that its board met February 16, 2012 to agree on recommendations for the company's 2012 Annual General Meeting of shareholders. The Board has set the meeting date as April 3, 2012.

The company said that at the board meeting, its board finalized proposals to be put to the Company's shareholders. Among the proposals was a recommendation that the shareholders re-elect the current directors and approve the appointment of a director candidate to the Board. The company stated that its board will recommend to the shareholders that the Company not declare a dividend in 2012.

The company noted that its Board also approved the CNH 2011 Statutory Accounts that will be presented to shareholders at the upcoming Annual General Meeting.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT